Most human invasive breast cancers (IBCs) appear to develop over long periods of time from certain pre-existing benign lesions. Of the many types of benign lesions in the human breast, only a few appear to have significant premalignant potential. The best characterized of these include atypical hyperplasias and in situ carcinomas and both categories are probably well on along the evolutionary pathway to IBC. Very little is known about earlier premalignant alterations. All types of premalignant breast lesions are relatively common but only a small proportion appear to progress to IBC. They are currently defined by their histological features and their prognosis is imprecisely estimated from indirect epidemiological evidence. Although lesions within specific categories look alike, they must possess underlying biological differences causing some to remain stable and others to progress. Recent studies suggest that they evolve by highly diverse genetic mechanisms and research into these altered pathways may identify specific early defects that can be targeted to prevent premalignant lesions from developing or becoming cancerous. It is far more rational to think that breast cancer can be prevented than cured once it has developed fully. This review discusses histological models of human premalignant breast disease that provide the framework for scientific investigations into the biological alterations behind them and examples of specific biological alterations that appear to be particularly important.

This article has been cited by other articles:

				T. A. Rose-Hellekant, A. J. Skildum, O. Zhdankin, A. L. Greene, R. R. Regal, K. D. Kundel, and D. W. Kundel Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor-Positive/Progesterone Receptor-Negative Mammary Tumors Cancer Prevention Research, May 1, 2009; 2(5): 496 - 502. [Abstract] [Full Text] [PDF]

				P. Simpson Linear and Nonlinear Models of Progression from In situ to Invasive Breast Cancer Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 105 - 109. [Full Text] [PDF]

				I. Mercier, M. C. Casimiro, J. Zhou, C. Wang, C. Plymire, K. G. Bryant, K. M. Daumer, F. Sotgia, G. Bonuccelli, A. K. Witkiewicz, et al. Genetic Ablation of Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-Like Mammary Lesions Am. J. Pathol., April 1, 2009; 174(4): 1172 - 1190. [Abstract] [Full Text] [PDF]

				I. Poola, J. Abraham, J. J. Marshalleck, Q. Yue, V. B. Lokeshwar, G. Bonney, and R. L. DeWitty Molecular Risk Assessment for Breast Cancer Development in Patients with Ductal Hyperplasias Clin. Cancer Res., February 15, 2008; 14(4): 1274 - 1280. [Abstract] [Full Text] [PDF]

				J. Bayliss, A. Hilger, P. Vishnu, K. Diehl, and D. El-Ashry Reversal of the Estrogen Receptor Negative Phenotype in Breast Cancer and Restoration of Antiestrogen Response Clin. Cancer Res., December 1, 2007; 13(23): 7029 - 7036. [Abstract] [Full Text] [PDF]

				R. E. Ellsworth, D. L. Ellsworth, B. Love, H. L. Patney, L. R. Hoffman, J. Kane, J. A. Hooke, and C. D. Shriver Correlation of Levels and Patterns of Genomic Instability With Histological Grading of DCIS Ann. Surg. Oncol., November 1, 2007; 14(11): 3070 - 3077. [Abstract] [Full Text] [PDF]

				W-D Han, Y-L Zhao, Y-G Meng, L Zang, Z-Q Wu, Q Li, Y-L Si, K Huang, J-M Ba, H Morinaga, et al. Estrogenically regulated LRP16 interacts with estrogen receptor {alpha} and enhances the receptor's transcriptional activity Endocr. Relat. Cancer, September 1, 2007; 14(3): 741 - 753. [Abstract] [Full Text] [PDF]

				B. J. Czerniecki, R. E. Roses, and G. K. Koski Development of Vaccines for High-Risk Ductal Carcinoma In situ of the Breast Cancer Res., July 15, 2007; 67(14): 6531 - 6534. [Abstract] [Full Text] [PDF]

				M. H. Herynk, I. Parra, Y. Cui, A. Beyer, M.-F. Wu, S. G. Hilsenbeck, and S. A.W. Fuqua Association between the Estrogen Receptor {alpha} A908G Mutation and Outcomes in Invasive Breast Cancer Clin. Cancer Res., June 1, 2007; 13(11): 3235 - 3243. [Abstract] [Full Text] [PDF]

				L. U. Rosenberg, K. Einarsdottir, E. I. Friman, S. Wedren, P. W. Dickman, P. Hall, and C. Magnusson Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2482 - 2488. [Abstract] [Full Text] [PDF]

				I. Poola, B. Shokrani, R. Bhatnagar, R. L. DeWitty, Q. Yue, and G. Bonney Expression of Carcinoembryonic Antigen Cell Adhesion Molecule 6 Oncoprotein in Atypical Ductal Hyperplastic Tissues Is Associated with the Development of Invasive Breast Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4773 - 4783. [Abstract] [Full Text] [PDF]

				C. S. Schuetz, M. Bonin, S. E. Clare, K. Nieselt, K. Sotlar, M. Walter, T. Fehm, E. Solomayer, O. Riess, D. Wallwiener, et al. Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis. Cancer Res., May 15, 2006; 66(10): 5278 - 5286. [Abstract] [Full Text] [PDF]

				R. E. Ellsworth, D. L. Ellsworth, B. Deyarmin, L. R. Hoffman, B. Love, J. A. Hooke, and C. D. Shriver Timing of Critical Genetic Changes in Human Breast Disease Ann. Surg. Oncol., December 1, 2005; 12(12): 1054 - 1060. [Abstract] [Full Text] [PDF]

				P. R. Nambiar, S. R. Boutin, R. Raja, and D. W. Rosenberg Global Gene Expression Profiling: A Complement to Conventional Histopathologic Analysis of Neoplasia Vet. Pathol., November 1, 2005; 42(6): 735 - 752. [Abstract] [Full Text] [PDF]

				I. S. Kristiansen, S. Fineberg, I. S. Kristiansen, P. M. Christensen, D. Gyrd-Hansen, D. W. Visscher, A. C. Degnim, L. C. Hartmann, J. G. Elmore, and G. Gigerenzer Benign breast disease and breast cancer. N. Engl. J. Med., October 27, 2005; 353(17): 1856 - 1858. [Full Text] [PDF]

				X. Cui, R. Schiff, G. Arpino, C. K. Osborne, and A. V. Lee Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy J. Clin. Oncol., October 20, 2005; 23(30): 7721 - 7735. [Abstract] [Full Text] [PDF]

				G. Arpino, R. Laucirica, and R. M. Elledge Premalignant and In Situ Breast Disease: Biology and Clinical Implications Ann Intern Med, September 20, 2005; 143(6): 446 - 457. [Abstract] [Full Text] [PDF]

				R. J. Santen and R. Mansel Benign Breast Disorders N. Engl. J. Med., July 21, 2005; 353(3): 275 - 285. [Full Text] [PDF]

				C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]

				D. Medina, F. S. Kittrell, J. Hill, A. Shepard, G. Thordarson, and P. Brown Tamoxifen Inhibition of Estrogen Receptor-{alpha}-Negative Mouse Mammary Tumorigenesis Cancer Res., April 15, 2005; 65(8): 3493 - 3496. [Abstract] [Full Text] [PDF]

				Q. J. Khan, B. F. Kimler, J. Clark, T. Metheny, C. M. Zalles, and C. J. Fabian Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 786 - 789. [Abstract] [Full Text] [PDF]

				C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]

				M. S. Frech, E. D. Halama, M. T. Tilli, B. Singh, E. J. Gunther, L. A. Chodosh, J. A. Flaws, and P. A. Furth Deregulated Estrogen Receptor {alpha} Expression in Mammary Epithelial Cells of Transgenic Mice Results in the Development of Ductal Carcinoma In situ Cancer Res., February 1, 2005; 65(3): 681 - 685. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, J. Anderson, O. W. Tawfik, M. S. Mayo, W. E. Burak Jr., J. A. O'Shaughnessy, K. S. Albain, D. M. Hyams, G. T. Budd, et al. Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator Clin. Cancer Res., August 15, 2004; 10(16): 5403 - 5417. [Abstract] [Full Text] [PDF]

				T. A. King, M. L. Gemignani, W. Li, D. D. Giri, K. S. Panageas, F. Bogomolniy, C. Arroyo, N. Olvera, M. E. Robson, K. Offit, et al. Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers Cancer Res., August 1, 2004; 64(15): 5051 - 5053. [Abstract] [Full Text] [PDF]

				A. S. Tsao, E. S. Kim, and W. K. Hong Chemoprevention of Cancer CA Cancer J Clin, May 1, 2004; 54(3): 150 - 180. [Abstract] [Full Text] [PDF]

				H. J. Burstein, K. Polyak, J. S. Wong, S. C. Lester, and C. M. Kaelin Ductal Carcinoma in Situ of the Breast N. Engl. J. Med., April 1, 2004; 350(14): 1430 - 1441. [Full Text] [PDF]

				P. E. Goss and K. Strasser-Weippl Prevention Strategies with Aromatase Inhibitors Clin. Cancer Res., January 1, 2004; 10(1): 372S - 379S. [Abstract] [Full Text] [PDF]

				X. Cui and A. V. Lee Regulatory Nodes That Integrate and Coordinate Signaling as Potential Targets for Breast Cancer Therapy Clin. Cancer Res., January 1, 2004; 10(1): 396S - 401S. [Abstract] [Full Text] [PDF]

				E. V. Schmidt Genes Involved in Breast Cancer Progression: Analysis of Global Changes in Gene Expression or Retroviral Tagging? Am. J. Pathol., December 1, 2002; 161(6): 1973 - 1977. [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al. A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117. [Abstract] [Full Text] [PDF]

				S. A. Gestl, M. D. Green, D. A. Shearer, E. Frauenhoffer, T. R. Tephly, and J. Weisz Expression of UGT2B7, a UDP-Glucuronosyltransferase Implicated in the Metabolism of 4-Hydroxyestrone and All-Trans Retinoic Acid, in Normal Human Breast Parenchyma and in Invasive and in Situ Breast Cancers Am. J. Pathol., April 1, 2002; 160(4): 1467 - 1479. [Abstract] [Full Text] [PDF]